15 active not recruiting. 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Active not recruiting 15 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) Prednisone - Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change | Phase 3 | Active not recruiting | The Hospital for Sick Children | 50 | 2024-11-01 | 2026-05-11 |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Povetacicept, Placebo (matched to Povetacicept) - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 605 | 2024-08-30 | 2026-05-15 |
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN) | Phase 3 | Active not recruiting | The Affiliated Hospital of Xuzhou Medical University | 150 | 2024-08-01 | 2025-08-01 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression Sefaxersen (RO7434656), Placebo - Primary IgA Nephropathy | Phase 3 | Active not recruiting | Hoffmann-La Roche | 459 | 2023-08-08 | 2026-10-28 |
| A Study of Zigakibart in Adults With IgA Nephropathy BION-1301, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 383 | 2023-07-06 | 2026-04-01 |
| Atacicept in Subjects With IgA Nephropathy Atacicept, Placebo to match Atacicept - IgA Nephropathy, Berger Disease | Phase 3 | Active not recruiting | Vera Therapeutics, Inc. | 428 | 2023-06-29 | 2026-10-01 |
| Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome Rituximab (genetical recombination), Placebo - Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic | Phase 3 | Active not recruiting | Shoichi Maruyama MD PhD | 88 | 2023-06-24 | 2026-08-12 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) Telitacicept, Placebo - Primary IgA Nephropathy | Phase 3 | Active not recruiting | RemeGen Co., Ltd. | 318 | 2023-04-28 | 2025-12-16 |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c. - Lupus Nephritis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 452 | 2022-07-14 | 2026-10-15 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) Sibeprenlimab 400 mg, Placebo - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 530 | 2022-03-15 | 2026-07-14 |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis Anifrolumab, Placebo - Lupus Nephritis | Phase 3 | Active not recruiting | AstraZeneca | 363 | 2022-02-15 | 2026-10-28 |
| Atrasentan in Patients With IgA Nephropathy Atrasentan, Placebo, Zigakibart - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 404 | 2020-12-11 | 2026-06-04 |
| A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis Obinutuzumab, MMF, Prednisone - Lupus Nephritis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 271 | 2020-08-10 | 2026-10-19 |
Glomerulonephritis, IGA (9) · Lupus Nephritis (3) · Renal Insufficiency, Chronic (3) · Kidney Diseases (2) · Lupus Erythematosus, Systemic (2) · Nephrosis, Lipoid (2) · Urologic Diseases (2) · Autoimmune Diseases (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · Immune System Diseases (1) · Nephritis (1) · Nephrotic Syndrome (1)
Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Male Urogenital Diseases (15) · Urogenital Diseases (15) · Nephritis (14) · Immune System Diseases (13) · Kidney Diseases (13) · Urologic Diseases (13) · Autoimmune Diseases (12) · Chronic Disease (3) · Connective Tissue Diseases (3) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Methylprednisolone (2) · Prednisolone (2) · Prednisone (2) · telitacicept (2) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Atrasentan (1) · Diphenhydramine (1) · Rituximab (1) · TACI receptor-IgG Fc fragment fusion protein (1) · anifrolumab (1) · ianalumab (1) · obinutuzumab (1)
Novartis Pharmaceuticals (3) · Hoffmann-La Roche (2) · Alexion Pharmaceuticals, Inc. (1) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1) · Apellis Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · RemeGen Co., Ltd. (1) · Shoichi Maruyama MD PhD (1) · The Affiliated Hospital of Xuzhou Medical University (1) · The Hospital for Sick Children (1) · Vera Therapeutics, Inc. (1)
United States (11) · Brazil (10) · China (10) · France (10) · Italy (10) · Argentina (9) · Germany (9) · Japan (9) · Spain (9) · United Kingdom (9) · Canada (8) · South Korea (8) · Taiwan (8) · Australia (7) · Czechia (7)
Eric Michael, MD (1) · Jicheng Lv, M.D. (1) · Rulan Parekh, MD MS (1) · Shoichi Shoichi, PhD, MD (1)
PMID 38299639, PMID 37528520, PMID 40465397, PMID 33693991, PMID 38059359, PMID 39331470, PMID 39455063, PMID 39460694, PMID 39462308, PMID 39513526, PMID 39927615, PMID 40482854, PMID 41196369, PMID 41211929, PMID 41426046, PMID 41442197, PMID 41620980, PMID 42127391, PMID 42133432, PMID 42175562, PMID 42205925, PMID 42242268, PMID 42633049, PMID 42713733
2023 (3), 2019 (1)